Brand against brand · semaglutide and tirzepatide
Wegovy vs Mounjaro
From the two FDA labels, read Published by PepVault
Wegovy is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist, from Eli Lilly.
FDA approved Wegovy for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes.
Label against label
| Compared | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Approved for | Weight reduction; heart risk with obesity; MASH (injection) | Type 2 diabetes (adults and children 10 and up); heart risk |
| Forms | Single-dose pen; Single-dose syringe; FlexTouch pen; Tablet | Single-dose pen or vial; Multi-dose vial or KwikPen |
| How often | once a week or once a day | once a week |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 2.5 mg a week |
| Top dose on the label | 7.2 mg a week (injection); 25 mg a day (tablets) | 15 mg a week |
| Most reported side effect | Nausea, 44% on 2.4 mg (placebo 16%) | Nausea, 18% on 15 mg (placebo 4%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2021 | 2022 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Wegovy injection, once a week
Wegovy tablets, once a day
Mounjaro, once a week

A missed dose, on each label
- Wegovy: For a missed injection, the label looks at the next scheduled dose: more than 2 days away, take the missed one as soon as possible; less than 2 days away, skip it. Missing 2 or more weeks in a row means starting the climb again from a lower dose.
- Mounjaro: A missed Mounjaro dose can still be given within 4 days (96 hours). After that it is skipped and the next one comes on the usual day.
The trial evidence
Questions
What is the difference between Wegovy and Mounjaro?
Wegovy is semaglutide, a GLP-1 receptor agonist; Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Wegovy and Mounjaro approved for?
Wegovy is approved for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes.
How often are Wegovy and Mounjaro taken?
Wegovy is taken once a week or once a day, as an injection or a tablet; Mounjaro once a week, as an injection.
What are the dose ranges of Wegovy and Mounjaro?
On their labels, Wegovy runs 0.25 mg to 7.2 mg once a week or 1.5 mg to 25 mg once a day, and Mounjaro 2.5 mg to 15 mg once a week. A prescriber sets the actual dose.
What is the most common side effect of Wegovy and Mounjaro?
On Wegovy’s label: nausea, 44% on 2.4 mg (placebo 16%). On Mounjaro’s: nausea, 18% on 15 mg (placebo 4%).
Sources
- WEGOVY (semaglutide) injection, for subcutaneous use, and WEGOVY (semaglutide) tablets, for oral use, FDA label on DailyMed (version 19, published Jun 30, 2026; read Nov 18, 2026)
- MOUNJARO (tirzepatide) injection, for subcutaneous use, FDA label on DailyMed (version 40, published Sep 2, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 215256 (Wegovy, the injection; application first approved 2021)
- Drugs@FDA, NDA 218316 (Wegovy, the tablets; application first approved 2025)
- Drugs@FDA, NDA 215866 (Mounjaro, the injection; application first approved 2022)
PepVault is not affiliated with Novo Nordisk. Wegovy is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Mounjaro is a trademark of its owner.